Fort Sheridan Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Fort Sheridan Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-280	Closed	-$216K	–	305
2026 Q1	$216K	Hold	280	–	–	0.03%	268
2025 Q4	$216K	Buy	+280	New	+$190K	0.03%	254
2024 Q4	–	Sell	-295	Closed	-$310K	–	256
2024 Q3	$310K	Hold	295	–	–	0.05%	199
2024 Q2	$310K	Buy	295 +50	+20%	+$48.5K	0.05%	186
2024 Q1	$236K	Hold	245	–	–	0.04%	180
2023 Q4	$215K	Sell	245 -50	-17%	-$41.2K	0.04%	183
2023 Q3	$243K	Hold	295	–	–	0.06%	163
2023 Q2	$212K	Hold	295	–	–	0.05%	182
2023 Q1	$242K	Hold	295	–	–	0.06%	167
2022 Q4	$213K	Hold	295	–	–	0.07%	172
2022 Q3	$203K	Buy	+295	New	+$186K	0.07%	171
2022 Q2	–	Sell	-295	Closed	-$206K	–	194
2022 Q1	$206K	Buy	+295	New	+$187K	0.06%	171
2021 Q4	–	Sell	-345	Closed	-$209K	–	207
2021 Q3	$209K	Buy	+345	New	+$214K	0.07%	171

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fort Sheridan Advisors's REGN Position: Q2 2026 in Review

Fort Sheridan Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 280 shares — an estimated $216K sold.

Fort Sheridan Advisors first reported a position in REGN in Q3 2021 and held it in 13 quarters. The position peaked at $310K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Fort Sheridan Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Fort Sheridan Advisors sold 280 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $216K.
Fort Sheridan Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 13 quarters.
Fort Sheridan Advisors's Regeneron Pharmaceuticals position peaked at $310K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Fort Sheridan Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.